{
    "clinical_study": {
        "@rank": "88897", 
        "brief_summary": {
            "textblock": "The aim of this study is to determine prospectively the value of a recently identified\n      proteomic signature in identifying those patients with lung cancer, who are likely to\n      benefit from and respond favourably to erlotinib therapy.\n\n      This is a prospective study of serum proteomics as a predictor of response to erlotinib\n      therapy."
        }, 
        "brief_title": "Tarceva. ICORG 08-41", 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Screening/Baseline\n\n        1. Routine blood tests (Haematology and Biochemistry) as per hospital practice\n\n        2. Research serum sample for proteomic studies (10ml blood sample)\n\n        3. Routine pre-treatment CT but with formal RECIST/WHO measurements of tumour size\n\n      2 months Post Commencement of Treatment with erlotinib: Routine CT with RECIST/WHO\n      assessment\n\n      4 months Post Commencement of Treatment with erlotinib: Routine CT with RECIST/WHO\n      assessment\n\n      1 year Post Commencement of Treatment with erlotinib (as per current standard of care):\n      Routine CT with RECIST/WHO assessment\n\n      Response Assessment: CT scans at baseline, at 2 and 4 months post commencement of therapy\n      and one year after treatment with erlotinib will be analyzed with the emphasis on\n      identification of disease progression.\n\n      Follow Up: Subsequent follow-up as per routine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or older\n\n          -  Any patient who is suited to receive CT scans as part of his/her routine care\n\n          -  Ability to understand and the willingness to sign a written informed consent, given\n             according to ICH/GCP, and national/local regulations. A signed informed consent must\n             be obtained prior to any study specific procedures\n\n          -  Planned treatment with erlotinib.\n\n        Exclusion Criteria:\n\n          -  Patients younger than 18 years of age\n\n          -  Patients not foreseen to receive TarcevaTM treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Any patient (18 years of age or older) diagnosed with non-small cell lung cancer at any\n        stage who is to be treated with erlotinib."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721252", 
            "org_study_id": "ICORG 08-41"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "non-small cell lung cancer", 
            "Erlotinib", 
            "TarcevaTM", 
            "proteomic signature"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cork", 
                        "country": "Ireland"
                    }, 
                    "name": "Cork University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "Beaumont Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "St James Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "The Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galway", 
                        "country": "Ireland"
                    }, 
                    "name": "Galway University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limerick", 
                        "country": "Ireland"
                    }, 
                    "name": "Mid-Western Regional Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louth", 
                        "country": "Ireland"
                    }, 
                    "name": "Our Lady Of Lourdes Hospital, Drogheda"
                }
            }
        ], 
        "location_countries": {
            "country": "Ireland"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Evaluation of a Proteomic Signature Developed to Identify Patients Likely to Benefit From Erlotinib (TarcevaTM), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Used in the Treatment of Non-small Cell Lung Cancer", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Ireland: Health Information and Quality Authority"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Routine CT with RECIST/WHO assessment", 
            "measure": "Value of a recently identified proteomic algorithm", 
            "safety_issue": "No", 
            "time_frame": "Change in CT scans taken at baseline, 2 and 4 months post commencement of therapy and one year after treatment with erlotinib will be analyzed with the emphasis on identification of disease progression."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721252"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "ICORG- All Ireland Cooperative Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ICORG- All Ireland Cooperative Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}